125802-18-8

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(3-fluorophenyl)cyclohexanamine hydrogen chloride is used as a chemical intermediate for the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows it to serve as a building block in the development of new drugs, potentially contributing to advancements in medicinal chemistry.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(3-fluorophenyl)cyclohexanamine hydrogen chloride is used as a compound with potential biological activity. Its structure may provide insights into the design of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Chemical Synthesis:
1-(3-fluorophenyl)cyclohexanamine hydrogen chloride is employed as a reagent in chemical synthesis processes, where its unique properties can be leveraged to create a variety of organic compounds with specific functionalities and applications.
Used in Material Science:
1-(3-fluorophenyl)cyclohexanamine hydrogen chloride may also find applications in material science, where its structural properties could be utilized in the development of new materials with tailored characteristics for various industries, such as electronics, automotive, or aerospace.

Upstream product

• 501-00-8 3-fluorophenylacetonitrile 
• 111-24-0 1,5-dibromo-pentane 
• 214262-91-6 1-(3-fluorophenyl)cyclohexanecarbonitrile 

Downstream Products

• 1375466-18-4 2-((1-(3-fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide 

Relevant academic research and scientific papers

INCREASING EXPRESSION OF INTERFERON REGULATED GENES WITH COMBINATONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS

Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.

COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS

The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS

The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of lymphoma in a subject in need thereof. Also provided herein are methods for treating lymphoma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.